Having spent several decades advising ophthalmologists on how to be better and smarter in growing their practices, it came as no surprise that many doctors were both amazed and confused as private equity firms (PE) began buying ophthalmic practices and paying large sums in the process, far outstripping any valuation offered upon retirement by a younger associate or another practice in the community.
Despite more than a decade of commercial availability, premium IOLs have not attracted their target audience, the patient-consumer who wants to see without glasses for most to all activities following surgery. According to Market Scope, market penetration has not gone beyond 10%…
Over the years, the value of an ophthalmic practice has been measured by its ability to grow, evaluating current performance against prior periods of services, revenue, active patients, locations and employees…
Of the many positives that came out of the private equity article I wrote last September is that ophthalmologists are beginning to understand the impact that even small changes in net income can have on the value of their practices…
I’m a big fan of new technology, even though looking back at some of my purchases I realize that new does not always mean better.
Take the Lytro camera for example, which claimed it would improve the image focus after you took the picture. Sounded good at the time, but It was an epic fail in the land of gizmos….
Sign up for SM2 Strategic’s monthly blog: